HS
KERX

HighVista Strategies’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

HighVista Strategies’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-171,300
Closed -$1M – 198
2016
Q4 		$1M Sell
171,300
-53,700
-24% -$293K 0.2% 114
2016
Q3 		$1.2M Buy
+225,000
New +$1.21M 0.22% 136

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return

HighVista Strategies's KERX Position: Q1 2017 in Review

HighVista Strategies sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2017, closing a stake of 171,300 shares — an estimated $1M sold.

HighVista Strategies first reported a position in KERX in Q3 2016 and held it in 2 quarters. The position peaked at $1.2M in Q3 2016. 119 funds tracked by Wall St. Rank hold KERX as of Q1 2017.

  • HighVista Strategies reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • HighVista Strategies sold 171,300 Keryx Biopharmaceuticals Inc shares in Q1 2017, an estimated $1M.
  • HighVista Strategies first reported a position in Keryx Biopharmaceuticals Inc in Q3 2016 and held it in 2 quarters.
  • HighVista Strategies's Keryx Biopharmaceuticals Inc position peaked at $1.2M in Q3 2016.
  • 119 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2017.

Based on HighVista Strategies's 13F filing for Q1 2017, filed 15 May 2017.